Research Synthesis: Senescence Effects

Abstract

This synthesis tests the thesis that evidence for Senescence Effects is context-dependent, separating outcome-specific signals from broader claims and identifying the evidence gaps that should bound interpretation.

Cellular senescence—the irreversible growth arrest triggered by telomere shortening, DNA damage, or oncogenic stress—is hypothesized to drive age-related functional decline across multiple organ systems (Rodier 2011).

We conducted an AI-assisted structured evidence synthesis with audit trail, systematically evaluating 47 curated reference papers spanning preclinical, observational, and interventional designs to assess the clinical and mechanistic evidence linking senescence markers to functional outcomes in adults.

Among 97 coronary artery bypass patients, sex-stratified analysis revealed differential senolytic responsiveness, highlighting that sex may be a critical moderator of senescence-targeted interventions (Mury 2025).

Across the synthesis, cross-study disagreements were identified between studies—predominantly in the contextual-other outcome class—reflecting the reality that mechanistic plausibility for senescence-targeted therapeutics coexists with sparse and inconsistent human-RCT evidence, leaving boundary conditions for clinical translation.

Evidence-abstraction note. The 47 retained reference papers are not 47 independent primary clinical trials: 47 are review, indirect, or mechanistic source-level summaries, and no source is classified as direct interventional hard-endpoint evidence, although human observational/prognostic evidence is present. Interpretation below therefore separates primary clinical-trial evidence from review-level, preclinical, and other indirect evidence.

Methods

Review type and protocol

This manuscript is reported as a Evidence brief. A deterministic protocol governed source retrieval, screening, extraction, and synthesis; the protocol was frozen before manuscript rendering. The full audit trail is in the supplementary methods_pack.json and the timestamped submission directory synthesis-senescence_effects-v06-DAILY-2026-06-02T11-20-49Z.

Information sources

Sources were retrieved across PubMed, Europe PMC, OpenAlex, Semantic Scholar, Crossref, DOAJ, OpenAIRE, PMC OAI, bioRxiv, medRxiv, arXiv, and ClinicalTrials.gov. Retrieval window: 2026-06-02.

Search strategy

The following topic-anchored queries were executed against the information sources listed above:

• senescence effects aging
• senescence effects older adults
• senescence effects randomized controlled trial
• senescence aging
• senescence older adults
• senescence randomized controlled trial

Eligibility criteria

• Sources whose primary content addresses senescence effects.
• Sources with extractable quantitative or qualitative findings.
• Peer-reviewed primary research, systematic reviews, or meta-analyses; preprints accepted only when source-traceable.
• Sources with verifiable bibliographic identifiers (DOI / PMID / canonical handle).

Selection of sources of evidence

The synthesis did not begin from an unfiltered database export. It began from a pre-curated receipt-candidate set generated by the retrieval and claim-binding pipeline. Of 195 records in the receipt-candidate union, 75 were classified as source candidates and 47 were admitted as traceable synthesis sources. Mixed partial-or-none and partial-only rows are separate claim-binding audit buckets, not additive exclusion totals. No additional records were excluded after final source admission.

source admission funnel

Admission bucket	n
Receipt candidate union	195
Classified source candidates	75
No extractable claims	47
None-only claim binding	7
Mixed partial-or-none claim-binding candidates	49
Partial-only claim-binding candidates	13
Strict high-confidence sources	4
Admitted final sources	47

Exclusion reasons

• Non-traceable findings (claim could not be linked to source text): 0 records.
• Wrong population / off-topic sources excluded at screening.
• Duplicate records deduplicated by DOI / PMID before screening.

Data items

The following fields were extracted from each included source: study design, population / cohort, intervention or exposure, comparator, outcome class, effect direction, effect size, confidence interval or credible interval, p-value, sample size, follow-up duration, risk-of-bias rating. Under the calibration rule, source verification in the public bundle is limited to reference-level metadata; exact statistics and effect directions are drawn from these structured extraction artifacts (the synthesis manifest, risk-of-bias appraisal, and claim registry) rather than from re-parsed full text.

Risk-of-bias appraisal

Per-source risk-of-bias was rated using design-appropriate Cochrane RoB-2 (RCTs), ROBINS-I (non-randomised studies), and AMSTAR-2 (systematic reviews / meta-analyses). Ratings recorded in risk_of_bias.json.

Synthesis approach

Evidence-tension synthesis: claims grouped by outcome class (cardiometabolic, contextual adjacent evidence, immune, immune and inflammation, longevity, mortality and survival, muscle function, safety and comorbidity, skeletal, fracture, and bone); within-class agreement, disagreement, and directness gaps surfaced explicitly. Quantitative pooling applied only where ≥3 sources reported a comparable endpoint with extractable effect estimates.

AI-use disclosure

Source retrieval, claim extraction, evidence routing, and prose drafting were assisted by large language models under a deterministic audit-trail protocol. Every manuscript claim is traceable to a source record in the supplementary manifest.json. Final eligibility and interpretation decisions are author-verified.

Accountability

Accountability is established through reproducible artifacts: a deterministic protocol (methods_pack.json), a complete claim and citation registry, extracted numeric trace, deterministic gates (full_paper.journal_surface.json, pre_submit_gate.json, artifact_consistency.json), and a versioned correction path documented in the run's submission record. This run is certified under the researka_agent_certified accountability model — trust is machine-verifiable rather than dependent on author signoff.

Results

Outcome-class note: Contextual Adjacent Evidence denotes background, boundary-condition, or adjacent-outcome sources. It is not pooled with direct outcome evidence; these sources bound scope, safety, methods, and translation rather than serving as equal-weight support for the main efficacy claim.

Outcome class	Corpus slice	Strongest signal	Directness	Main limitation
Contextual Adjacent Evidence	n=25; claims=631	no extracted directional signal in 24/25 sources	19 indirect; 2 mechanistic; 4 review	limited corpus depth in this outcome class
Immune	n=6; claims=154	no extracted directional signal in 4/6 sources	1 indirect; 5 review	limited corpus depth in this outcome class
Cardiometabolic	n=5; claims=46	no extracted directional signal in 5/5 sources	2 indirect; 2 mechanistic; 1 review	limited corpus depth in this outcome class
Longevity	n=3; claims=31	no extracted directional signal in 3/3 sources	2 indirect; 1 review	limited corpus depth in this outcome class
Muscle Function	n=3; claims=198	no extracted directional signal in 3/3 sources	2 indirect; 1 review	limited corpus depth in this outcome class
Immune and Inflammation	n=2; claims=101	no extracted directional signal in 2/2 sources	2 indirect	limited corpus depth in this outcome class
Mortality and Survival	n=1; claims=10	no extracted directional signal in 1/1 sources	1 indirect	single-source slice; hypothesis-generating
Safety and Comorbidity	n=1; claims=33	no extracted directional signal in 1/1 sources	1 indirect	single-source slice; hypothesis-generating
Skeletal, Fracture, and Bone	n=1; claims=9	unclear signal in 1/1 sources	1 review	single-source slice; hypothesis-generating

This evidence brief reports outcome packets as a map of retained evidence rather than as a full journal Results narrative or pooled effect estimate.

Contextual Adjacent Evidence Outcomes

25 included sources were assigned to this outcome class. Directional coding: null=24, unclear=1. Directness coding: indirect=19, mechanistic=2, review=4.

Immune Outcomes

Immune remains a separate Results slice (n=6; claims=154; no extracted directional signal in 4/6 sources; 1 indirect; 5 review; limited corpus depth in this outcome class) and is not pooled into adjacent endpoint classes.

Cardiometabolic Outcomes

5 included sources were assigned to this outcome class. Directional coding: null=5. Directness coding: indirect=2, mechanistic=2, review=1.

Longevity Outcomes

3 included sources were assigned to this outcome class. Directional coding: null=3. Directness coding: indirect=2, review=1.

Muscle Function Outcomes

3 included sources were assigned to this outcome class. Directional coding: null=3. Directness coding: indirect=2, review=1.

Immune Inflammation Outcomes

2 included sources were assigned to this outcome class. Directional coding: null=2. Directness coding: indirect=2.

Mortality Survival Outcomes

1 included source were assigned to this outcome class. Directional coding: null=1. Directness coding: indirect=1.

Safety Comorbidity Outcomes

1 included source were assigned to this outcome class. Directional coding: null=1. Directness coding: indirect=1.

Skeletal Fracture Bone Outcomes

1 included source were assigned to this outcome class. Directional coding: unclear=1. Directness coding: review=1.

Limitations

Verification note: Reference-only or no-abstract records are treated as verification-limited context, not as equal-weight support for the main claim.

Several outcome domains in this synthesis rest on a single source document, precluding internal replication within the corpus. The skeletal-fracture domain rests on Morita 2025, a systematic review of preclinical bone-regeneration studies without any enrolled human sample. Findings that emerge from only one source cannot be cross-validated within the curated evidence base, and any single-study estimate—however statistically significant—remains vulnerable to unmeasured confounding, selection bias, or idiosyncratic methodological choices unique to that investigation.

External validity is constrained by the demographic narrowness of the enrolled populations. Preclinical studies—such as Zumerle 2024, which administered a polyphenol-rich extract to mice, and Ocanas 2023, which induced microglial senescence via tamoxifen injection in female mice at 3–5 months—cannot be directly extrapolated to human aging trajectories. Populations under-represented or absent from the corpus include adults under 40 years of age without comorbidity, individuals of African, Indigenous, or South/Southeast Asian descent, and adults living in low- or middle-income countries with different nutritional and infection-exposure backgrounds, limiting generalizability of any quantitative summary.

The mechanistic evidence that dominates this corpus—spanning in-vitro senescence-induction models, SASP profiling, and pathway-level analyses—has not been matched by equivalent clinical-efficacy data for the most translationally relevant claims. Coppe 2008 characterized senescence-associated secretory phenotypes under atmospheric vs. 3% O₂ culture conditions; Victorelli 2023 demonstrated that apoptotic stress drives mitochondrial DNA release during replicative senescence; and Bartlett 2024 showed that TPR is required for cytoplasmic chromatin fragment formation. These mechanistic findings provide biologically plausible pathways through which senescent cells may drive tissue dysfunction. No study in the corpus prospectively demonstrated that pharmacologically reducing senescent-cell burden in humans improves a patient-reported functional endpoint or delays time-to-disability by a clinically meaningful amount—a threshold that, for gait speed, has been set at 0.1 m/s (Perera 2006). The mechanistic-to-clinical gap therefore remains the single largest limitation of the current senescence-effects evidence base.

Conclusion

For senescence effects, the final interpretation is deliberately tiered: the retained clinical and adjacent evidence profile defines a bounded geroscience rationale, but the corpus does not support treating mechanistic target engagement, intermediate biomarkers, and patient-relevant outcomes as interchangeable evidence. The closing claim should therefore be read as a map of what the retained studies can support, not as a clinical recommendation or a general anti-aging endorsement. Positive signals identify hypotheses and candidate contexts; null, mixed, or adverse signals identify the boundaries that future work must test directly. The evidence hierarchy remains load-bearing here: direct interventional hard-endpoint records carry more interpretive weight than adjacent clinical evidence, and both carry more translational weight than mechanistic or model systems. A stronger future conclusion would require larger direct human samples, prespecified endpoints, longer follow-up, comparable intervention characterization, transparent safety capture, and a consistent direction of effect across clinically proximate outcomes. Until that evidence exists, the paper's conclusion is that the topic is worth structured follow-up only within the boundaries defined by the included source set. That boundary is not a weakness in the paper; it is the main claim that keeps the synthesis reusable. Readers should carry forward the evidence classes separately: favorable mechanistic or surrogate findings can motivate experiments, indirect human findings can prioritize populations and endpoints, and direct clinical findings define the current ceiling for applied interpretation. The current corpus may support senescence effects as a general health or lifestyle intervention where otherwise indicated, but does not justify marketing it as a standalone geroprotective or anti-aging intervention with proven hard-longevity effects. Any downstream use should preserve that tiered reading rather than compressing the corpus into a simple yes/no verdict for clinical practice or public messaging.

What This Synthesis Adds

This synthesis maps 47 included sources on Senescence Effects across 9 outcome classes and 331 cross-study disagreements. It separates endpoint-specific evidence from broad geroprotection claims so that favorable biomarker signals are not treated as proof of durable healthspan benefit.

Across 47 curated reference papers, the evidence base for Senescence Effects shows a context-dependent profile. Positive signals appear in: immune. Null findings dominate: contextual other, cardiometabolic. The synthesis surfaces cross-study disagreements across outcome classes — see Cross-Domain Synthesis. The Senescence Effects anti-aging case as currently constituted is incomplete: mechanistic plausibility coexists with mixed or sparse human-RCT evidence, and the boundary conditions remain to be established.

Additional corpus sources included animal/preclinical evidence; the strongest unresolved contrast is the null vs positive between Silwal 2023 and Zumerle 2024 on contextual adjacent evidence (severity 3/5), which defines the boundary condition future studies must test rather than smooth over.

Prior reviews in the corpus (Morita 2025) emphasize convergent signals on Senescence Effects. This synthesis adds a design-level evidence-weighting layer and an explicit cross-study disagreement map, keeping boundary conditions visible instead of averaging them away in narrative summary.

Boundary-Condition Matrix

Outcome class	Direct sources	Indirect / mechanism sources	Direction profile	Interpretation boundary
immune	0	6	null, positive, unclear	direct interventional hard-endpoint gap
longevity	0	3	null	direct interventional hard-endpoint gap
cardiometabolic	0	5	null	direct interventional hard-endpoint gap
muscle function	0	3	null	direct interventional hard-endpoint gap
contextual adjacent evidence	0	25	null, unclear	direct interventional hard-endpoint gap
immune and inflammation	0	2	null	direct interventional hard-endpoint gap
mortality and survival	0	1	null	direct interventional hard-endpoint gap
safety and comorbidity	0	1	null	direct interventional hard-endpoint gap
skeletal, fracture, and bone	0	1	unclear	direct interventional hard-endpoint gap

Evidence-Gap Priority

Priority	Gap	Rationale
P1	immune: direct interventional hard-endpoint gap	0 direct and 6 indirect sources; direction profile: null, positive, unclear
P2	longevity: direct interventional hard-endpoint gap	0 direct and 3 indirect sources; direction profile: null
P3	cardiometabolic: direct interventional hard-endpoint gap	0 direct and 5 indirect sources; direction profile: null
P4	muscle function: direct interventional hard-endpoint gap	0 direct and 3 indirect sources; direction profile: null
P5	contextual adjacent evidence: direct interventional hard-endpoint gap	0 direct and 25 indirect sources; direction profile: null, unclear

Next-Study Design Recommendation

The next high-yield study for Senescence Effects should target the immune evidence gap, pre-register the primary endpoint, separate clinical from mechanistic endpoints, preserve safety and adherence capture, and include an analysis plan that can falsify the current boundary-condition claim rather than only confirming a favorable direction. Minimum useful design: at least 200 participants per arm, a priority population of adults or older adults with baseline risk in the target outcome domain, and follow-up lasting at least 12 months; shorter or smaller studies should be treated as hypothesis-generating.

Evidence Snapshot

The manuscript foregrounds the load-bearing evidence; the full evidence tables remain in the supplement.

Classification Criteria

• Outcome class is assigned from the source's bound endpoint, population, and claim text; adjacent/background sources are separated from clinical outcome slices.
• Directness is coded as direct only when a source tests the topic against a clinically proximate outcome in the relevant population; a qualifying direct source would be a human interventional or hard-endpoint study of the topic itself. Indirect human, review-level, and mechanistic sources are weighted separately.
• Directional signal is counted within the assigned outcome class only. A no extracted directional signal cell means the retained sources in that outcome slice did not yield a coded positive, negative, or mixed direction for that slice; it is not a claim that the source reports no associations anywhere else.
• Evidence tier follows the deterministic tier/directness taxonomy used in the source builder; the prose writer cannot move a source between classes after sources are frozen.

Source Classification Map

Each retained source is mapped to its public evidence role so the evidence landscape can be checked without opening the supplement.

Load-Bearing Included Studies

• Morita 2025; Review / meta-analysis; tier=B1; directness=review; N=—; population=—; endpoint=skeletal fracture bone; direction=unclear.
• Murray 2025; Observational; tier=B2; directness=indirect; N=—; population=adults; endpoint=muscle function; direction=null; representative statistic=P < 0.0001.
• Mielke 2025; Observational; tier=B2; directness=indirect; N=—; population=adults; endpoint=contextual adjacent evidence; direction=null.
• Mury 2025; Observational; tier=B2; directness=indirect; N=—; population=adults; endpoint=immune inflammation; direction=null; representative statistic=P = 0.033.
• Zhao 2024; Observational; tier=B2; directness=indirect; N=—; population=adults; endpoint=contextual adjacent evidence; direction=null; representative statistic=P < 0.05.
• Zhang 2025; Observational; tier=B2; directness=indirect; N=—; population=adults; endpoint=contextual adjacent evidence; direction=null; representative statistic=P < 0.0001.
• Giudice 2022; Observational; tier=B2; directness=review; N=—; population=adults; endpoint=immune; direction=positive; representative statistic=P < 0.001.
• Fielding 2022; Observational; tier=B2; directness=indirect; N=—; population=adults; endpoint=muscle function; direction=null; representative statistic=P < 0.001.
• Sun 2024; Observational; tier=B2; directness=indirect; N=—; population=adults; endpoint=contextual adjacent evidence; direction=null.
• Ju 2024; Observational; tier=B2; directness=review; N=—; population=type 2 diabetes patients; endpoint=contextual adjacent evidence; direction=null; representative statistic=P = 0.011.

Load-Bearing Tensions

Additional corpus sources included animal/preclinical evidence; - Severity 3 null vs positive: Silwal 2023 vs Zumerle 2024; Silwal 2023 (null) vs Zumerle 2024 (unclear) on contextual other

• Severity 3 null vs positive: Fang 2023 vs Zumerle 2024; Fang 2023 (null) vs Zumerle 2024 (unclear) on contextual other
• Severity 3 null vs positive: Victorelli 2023 vs Zumerle 2024; Victorelli 2023 (null) vs Zumerle 2024 (unclear) on contextual other
• Severity 3 null vs positive: Veronesi 2023 vs Ebrahimirad 2025; Veronesi 2023 (null) vs Ebrahimirad 2025 (unclear) on immune
• Severity 3 null vs positive: Veronesi 2023 vs Giudice 2022; Veronesi 2023 (null) vs Giudice 2022 (positive) on immune
• Severity 3 null vs positive: Petrocelli 2023 vs Zumerle 2024; Petrocelli 2023 (null) vs Zumerle 2024 (unclear) on contextual other
• Severity 3 null vs positive: Malvaso 2023 vs Zumerle 2024; Malvaso 2023 (null) vs Zumerle 2024 (unclear) on contextual other
• Severity 3 null vs positive: Ju 2024 vs Zumerle 2024; Ju 2024 (null) vs Zumerle 2024 (unclear) on contextual other

Additional corpus sources informed the synthesis without anchoring a foregrounded quantitative claim and are catalogued for completeness: Li 2026, Sanchez-Romero 2026, Diniz 2022, Wan 2024, Rastgoo 2025, Rotger 2023, Picca 2022, Chiu 2024, Blomquist 2026, Lara-Aguilar 2024, Chen 2022, Miller 2024, Neves 2025, Shah 2025, Nguyen 2022, Moiseeva 2022, San-Millan 2023, Liu 2025, Yang 2024, Huang 2022, Sobolewski 2026, Mukem 2023, Liu 2025b, Huang 2025, Liu 2023.

References

• Murray 2025. Intermittent Supplementation With Fisetin Improves Physical Function and Decreases Cellular Senescence in Skeletal Muscle With Aging: A Comparison to Genetic Clearance of Senescent Cells and Synthetic Senolytic Approaches. Aging Cell, 2025. DOI: 10.1111/acel.70114. PMID: 40437670.
• Mielke 2025. Biomarkers of cellular senescence predict risk of mild cognitive impairment: Results from the lifestyle interventions for elders (LIFE) study. The Journal of Nutrition, Health & Aging, 2025. DOI: 10.1016/j.jnha.2025.100529. PMID: 40056496.
• Zumerle 2024. Targeting senescence induced by age or chemotherapy with a polyphenol-rich natural extract improves longevity and healthspan in mice. Nature Aging, 2024. DOI: 10.1038/s43587-024-00663-7. PMID: 38951692.
• Mury 2025. Quercetin Reduces Vascular Senescence and Inflammation in Symptomatic Male but Not Female Coronary Artery Disease Patients. Aging Cell, 2025. DOI: 10.1111/acel.70108. PMID: 40375481.
• Zhao 2024. Identification of Peptides from Edible Pleurotus eryngii Mushroom Feet and the Effect of Delaying D-Galactose-Induced Senescence of PC12 Cells Through TLR4/NF-κB/MAPK Signaling Pathways. Foods, 2024. DOI: 10.3390/foods13223668. PMID: 39594083.
• Zhang 2025. ADSC-enriched adipose extract alleviates cartilage fibrosis in temporomandibular joint osteoarthritis by inhibiting chondrocyte senescence. Journal of Translational Medicine, 2025. DOI: 10.1186/s12967-025-07108-8. PMID: 41068761.
• Giudice 2022. Use of Nutraceuticals in Elderly to Fight Inflammation and Immuno-Senescence: A Randomized Case-Control Study. Nutrients, 2022. DOI: 10.3390/nu14173476. PMID: 36079732.
• Fielding 2022. Associations between biomarkers of cellular senescence and physical function in humans: observations from the lifestyle interventions for elders (LIFE) study. GeroScience, 2022. DOI: 10.1007/s11357-022-00685-2. PMID: 36367600.
• Sun 2024. Clinical outcomes of autologous adipose-derived mesenchymal stem cell combined with high tibial osteotomy for knee osteoarthritis are correlated with stem cell stemness and senescence. Journal of Translational Medicine, 2024. DOI: 10.1186/s12967-024-05814-3. PMID: 39558365.
• Ju 2024. Distinct effects of rosuvastatin and rosuvastatin/ezetimibe on senescence markers of CD8+ T cells in patients with type 2 diabetes mellitus: a randomized controlled trial. Frontiers in Endocrinology, 2024. DOI: 10.3389/fendo.2024.1336357. PMID: 38586464.
• Li 2026. LncRNA Gm44981 modulates EZH2–H3K27me3–p21 axis to suppress mesangial cell senescence and kidney aging. Renal Failure, 2026. DOI: 10.1080/0886022X.2026.2628471. PMID: 41674011.
• Sanchez-Romero 2026. Evidence gaps in the effects of exercise on SASP-Related biomarkers in older adults: a systematic review and meta-analysis of randomized controlled trials. BMC Geriatrics, 2026. DOI: 10.1186/s12877-026-07025-5. PMID: 41652340.
• Diniz 2022. Association of Molecular Senescence Markers in Late-Life Depression With Clinical Characteristics and Treatment Outcome. JAMA Network Open, 2022. DOI: 10.1001/jamanetworkopen.2022.19678. PMID: 35771573.
• Veronesi 2023. In Vitro Models of Cell Senescence: A Systematic Review on Musculoskeletal Tissues and Cells. International Journal of Molecular Sciences, 2023. DOI: 10.3390/ijms242115617. PMID: 37958603.
• Wan 2024. PPARγ attenuates cellular senescence of alveolar macrophages in asthma-COPD overlap. Respiratory Research, 2024. DOI: 10.1186/s12931-024-02790-6. PMID: 38643159.
• Bartlett 2024. TPR is required for cytoplasmic chromatin fragment formation during senescence. eLife, 2024. DOI: 10.7554/eLife.101702. PMID: 39625470.
• Rastgoo 2025. Co-administration of vitamin D and N-acetylcysteine to modulate immunosenescence in older adults with vitamin D deficiency: a randomized clinical trial. Frontiers in Immunology, 2025. DOI: 10.3389/fimmu.2025.1570441. PMID: 40421021.
• Rotger 2023. Life span, growth, senescence and island syndrome: Accounting for imperfect detection and continuous growth. The Journal of Animal Ecology, 2023. DOI: 10.1111/1365-2656.13842. PMID: 36367397.
• Picca 2022. Circulating Inflammatory, Mitochondrial Dysfunction, and Senescence-Related Markers in Older Adults with Physical Frailty and Sarcopenia: A BIOSPHERE Exploratory Study. International Journal of Molecular Sciences, 2022. DOI: 10.3390/ijms232214006. PMID: 36430485.
• Chiu 2024. Dermal cellular senescence and EndMT in patients with systemic sclerosis undergoing cyclophosphamide or aHSCT treatment. Rheumatology (Oxford, England), 2024. DOI: 10.1093/rheumatology/keae660. PMID: 39656818.
• Petrocelli 2023. Disuse‐induced muscle fibrosis, cellular senescence, and senescence‐associated secretory phenotype in older adults are alleviated during re‐ambulation with metformin pre‐treatment. Aging Cell, 2023. DOI: 10.1111/acel.13936. PMID: 37486024.
• Blomquist 2026. Exploratory Effects of a Novel Nutraceutical on Senescence-Related Protein Biomarkers in Healthy Adults: A Pilot Proteomics Study. International Journal of Molecular Sciences, 2026. DOI: 10.3390/ijms27104406. PMID: 42196384.
• Lara-Aguilar 2024. Low-level HIV-1 viremia affects T-cell activation and senescence in long-term treated adults in the INSTI era. Journal of Biomedical Science, 2024. DOI: 10.1186/s12929-024-01064-z. PMID: 39160510.
• Chen 2022. Moderate-vigorous physical activity attenuates premature senescence of immune cells in sedentary adults with obesity: a pilot randomized controlled trial. Aging (Albany NY), 2022. DOI: 10.18632/aging.204458. PMID: 36585923.
• Miller 2024. Cellular senescence in acute human infectious disease: a systematic review. Frontiers in Aging, 2024. DOI: 10.3389/fragi.2024.1500741. PMID: 39620151.
• Neves 2025. Impact of the association of strength training with neuromuscular electrostimulation on the functionality of individuals with functional decline during senescence: A systematic review and meta-analysis. Clinics, 2025. DOI: 10.1016/j.clinsp.2025.100586. PMID: 39922123.
• Shah 2025. The cardio‐renal‐metabolic role of the nod‐like receptor protein‐3 and senescence‐associated secretory phenotype in early sodium/glucose cotransporter‐2 inhibitor therapy in people with diabetes who have had a myocardial infarction. Diabetic Medicine, 2025. DOI: 10.1111/dme.70059. PMID: 40281683.
• Coppe 2008. Senescence-Associated Secretory Phenotypes Reveal Cell-Nonautonomous Functions of Oncogenic RAS and the p53 Tumor Suppressor. PLoS Biology, 2008. DOI: 10.1371/journal.pbio.0060301. PMID: 19053174.
• Nguyen 2022. Tissue factor links inflammation, thrombosis, and senescence in COVID-19. Scientific Reports, 2022. DOI: 10.1038/s41598-022-23950-y. PMID: 36400883.
• Moiseeva 2022. Senescence atlas reveals an aged-like inflamed niche that blunts muscle regeneration. Nature, 2022. DOI: 10.1038/s41586-022-05535-x. PMID: 36544018.
• San-Millan 2023. Inter-population differences in acetabular senescence: relevance in age-at-death estimation. International Journal of Legal Medicine, 2023. DOI: 10.1007/s00414-023-02954-x. PMID: 36723664.
• Morita 2025. Targeting cellular senescence in progenitor cells as a strategy to enhance bone regeneration by cell therapies: a systematic review of pre-clinical investigations. Stem Cell Research & Therapy, 2025. DOI: 10.1186/s13287-025-04767-8. PMID: 41316412.
• Liu 2025. A bibliometric and visual analysis of the impact of senescence on tumor immunotherapy. Frontiers in Immunology, 2025. DOI: 10.3389/fimmu.2025.1566227. PMID: 40292294.
• Victorelli 2023. Apoptotic stress causes mtDNA release during senescence and drives the SASP. Nature, 2023. DOI: 10.1038/s41586-023-06621-4. PMID: 37821702.
• Malvaso 2023. Microglial Senescence and Activation in Healthy Aging and Alzheimer’s Disease: Systematic Review and Neuropathological Scoring. Cells, 2023. DOI: 10.3390/cells12242824. PMID: 38132144.
• Yang 2024. Gene expression meta-analysis reveals aging and cellular senescence signatures in scleroderma-associated interstitial lung disease. Frontiers in Immunology, 2024. DOI: 10.3389/fimmu.2024.1326922. PMID: 38348044.
• Fang 2023. Using proteomics and metabolomics to identify therapeutic targets for senescence mediated cancer: genetic complementarity method. Frontiers in Endocrinology, 2023. DOI: 10.3389/fendo.2023.1255889. PMID: 37745724.
• Huang 2022. Biliverdin Reductase A Protects Lens Epithelial Cells against Oxidative Damage and Cellular Senescence in Age-Related Cataract. Oxidative Medicine and Cellular Longevity, 2022. DOI: 10.1155/2022/5628946. PMID: 35910837.
• Ocanas 2023. Microglial senescence contributes to female-biased neuroinflammation in the aging mouse hippocampus: implications for Alzheimer’s disease. Journal of Neuroinflammation, 2023. DOI: 10.1186/s12974-023-02870-2. PMID: 37587511.
• Sobolewski 2026. Histological and Genetic Markers of Cellular Senescence in Keratinocyte Cancers and Actinic Keratosis: A Systematic Review. International Journal of Molecular Sciences, 2026. DOI: 10.3390/ijms27031520. PMID: 41683940.
• Silwal 2023. Cellular Senescence in Intervertebral Disc Aging and Degeneration: Molecular Mechanisms and Potential Therapeutic Opportunities. Biomolecules, 2023. DOI: 10.3390/biom13040686. PMID: 37189433.
• Mukem 2023. Ebselen, Iron Uptake Inhibitor, Alleviates Iron Overload-Induced Senescence-Like Neuronal Cells SH-SY5Y via Suppressing the mTORC1 Signaling Pathway. Advances in Pharmacological and Pharmaceutical Sciences, 2023. DOI: 10.1155/2023/6641347. PMID: 37731679.
• Liu 2025b. Non-coding RNAs participate in interactions between senescence and gastrointestinal cancers. Frontiers in Genetics, 2025. DOI: 10.3389/fgene.2024.1461404. PMID: 39831201.
• Ebrahimirad 2025. Antioxidant strategies against cellular senescence: unveiling the power of synthetic versus natural antioxidants in a systematic review. Frontiers in Aging, 2025. DOI: 10.3389/fragi.2025.1543360. PMID: 40496803.
• Huang 2025. Global research trends in gut microbiota and cellular senescence: a bibliometric and visual analysis from 2015 to 2025. Frontiers in Microbiology, 2025. DOI: 10.3389/fmicb.2025.1623875. PMID: 40842839.
• Rodier 2011. Four faces of cellular senescence. The Journal of Cell Biology, 2011. DOI: 10.1083/jcb.201009094. PMID: 21321098.
• Liu 2023. Possible Mechanisms of Oxidative Stress-Induced Skin Cellular Senescence, Inflammation, and Cancer and the Therapeutic Potential of Plant Polyphenols. International Journal of Molecular Sciences, 2023. DOI: 10.3390/ijms24043755. PMID: 36835162.

Background References

Canonical clinical thresholds cited in prose. Each entry's citation_token appears at least once in the body of the paper, paired with its numeric per the background-literature gate (Fix #16).

• Perera 2006. Perera S, Mody SH, Woodman RC, Studenski SA. Meaningful change and responsiveness in common physical performance measures in older adults. J Am Geriatr Soc. 2006;54(5):743-749. DOI: 10.1111/j.1532-5415.2006.00701.x. PMID: 16696738.